Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma

Authors:	Fateeha Furqan Kwang W. Ahn Yue Chen Manmeet Kaur Syed A. Abutalib Nausheen Ahmed Sairah Ahmed Mohamed A. Kharfan-Dabaja Johnathan Friedberg Tara Gregory LaQuisa Hill Cole Sterling Stephan K. Barta Mazyar Shadman Miguel-Angel Perales Jasmine Zain Alex F. Herrera Craig Sauter Mehdi Hamadani

Affiliation:	1. BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA;2. Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA;3. Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA;4. Co-Director, Hematology & BMT/Cellular Therapy, Medical Director, NMDP Apheresis Midwest Program Associate Professor, Rosalind Franklin University of Medicine and Science CTCA, Part of City of Hope, Zion, Illinois, USA;5. Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, Kansas, USA;6. Departments of Lymphoma/Myeloma and Stem Cell Transplantation/Cellular Therapy UT MD Anderson Cancer Center, Houston, Texas, USA;7. Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, Florida, USA;8. University of Rochester, Wilmot Cancer Institute, Department of Medicine;9. Colorado Blood Cancer Institute, Denver, CO and Sarah Cannon Research Institute, Nashville, Tennessee, USA;10. Center for Cell and Gene Therapy, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA;11. Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;12. Division of Hematology and Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA;13. Clinical Research Division, Fred Hutch Cancer Center and Medical Oncology Division, University of Washington, Seattle, Washington, USA;14. Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center;15. Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA;16. Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA

Abstract:	The prognosis of relapsed/refractory (R/R) anaplastic large cell lymphoma (ALCL) is poor. Large studies evaluating outcomes of allogeneic haematopoietic cell transplantation (allo-HCT) in systemic R/R ALCL are not available. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we evaluated outcomes of 182 adults (aged ≥18 years) with R/R ALCL undergoing allo-HCT between 2008 and 2019. Non-relapse mortality (NRM), disease relapse/progression (REL), progression-free survival (PFS), and overall survival (OS) were modelled using Cox proportional hazards models. The median (range) follow-up of survivors was 62 (3–148) months. The 1-year NRM was 18%. The 5-year REL, PFS and OS were 32%, 41% and 56% respectively. On multivariable regression analysis African American race (hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.6–4.8; p < 0.001) and refractory disease at allo-HCT (HR 3.2, 95% CI 1.6–6.2; p < 0.001) were predictive of inferior OS. Similarly, African-American race (HR 2.1, 95% CI 1.3–3.4; p = 0.003), other minority race (HR 2.5, 95% CI 1.2–5.3; p = 0.02) and refractory disease (HR 2.2, 95% CI 1.2–4.3; p = 0.01) were predictive of inferior PFS. These data, demonstrate that allo-HCT can result in durable disease control in a sizable proportion of patients with R/R ALCL. Refractory disease and racial minority status predicted inferior allo-HCT outcomes. Whether the inferior outcomes of racial minorities with R/R ALCL after allo-HCT are driven by differences in disease biology or disparities in post allo-HCT care, or both, requires further investigation.

Keywords:	anaplastic large cell lymphoma allogeneic transplantation graft-versus-host disease graft versus leukaemia

设为首页 | 免责声明 | 关于勤云 | 加入收藏